A Phase 2 dose ranging study of ATI-50001 for the oral treatment of alopecia totalis and alopecia universalis

Trial Profile

A Phase 2 dose ranging study of ATI-50001 for the oral treatment of alopecia totalis and alopecia universalis

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs ATI 50001 (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Mar 2017 According to an Aclaris Therapeutics media release, the company is planning to initiate this trial in the second half of 2017.
    • 16 Nov 2016 New trial record
    • 03 Nov 2016 According to an Aclaris Therapeutics media release, the company is planning to commence this trial in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top